2,154 Shares in DaVita Inc. (NYSE:DVA) Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. bought a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,154 shares of the company's stock, valued at approximately $322,000.

A number of other large investors have also recently modified their holdings of the company. Invesco Ltd. boosted its holdings in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares during the period. Northern Trust Corp boosted its holdings in shares of DaVita by 12.5% in the fourth quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after purchasing an additional 82,326 shares during the period. Amundi lifted its holdings in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares during the period. Epoch Investment Partners Inc. purchased a new stake in DaVita during the fourth quarter worth $55,100,000. Finally, KBC Group NV lifted its holdings in DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after buying an additional 2,636 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DVA. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Truist Financial lowered their target price on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Stock Down 0.2%

Shares of DVA stock traded down $0.22 during trading hours on Friday, reaching $138.30. 605,497 shares of the company's stock were exchanged, compared to its average volume of 827,645. The stock's 50 day moving average is $145.32 and its 200-day moving average is $153.35. The company has a market cap of $10.44 billion, a price-to-earnings ratio of 12.88, a P/E/G ratio of 1.07 and a beta of 1.14. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the prior year, the firm posted $2.26 earnings per share. The business's quarterly revenue was up 5.0% on a year-over-year basis. Analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.